Alembic Pharmaceuticals share news and announcements
NSE: APLLTDBSE: 533573Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹781.30.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,941 Cr430th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 4 Aug 2026
- 21.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 May 2026
- 2.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.58%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 4 Aug 2026
- 12.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 4 Aug 2026
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 May 2026
- 0.24
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,20,84752.2% delivered
Alembic Pharmaceuticals routine notices
389 filed, newest first. Page 3 of 8.
May 2024
27 May · Routine
24 May · Routine
20 May · Routine
17 May · Routine
14 May · Routine
11 May · Routine
10 May · Routine
6 May · Routine
3 May · Routine
2 May · Routine
1 May · Routine
1 May · Routine
Apr 2024
30 Apr · Routine
25 Apr · Routine
23 Apr · Routine
19 Apr · Routine
17 Apr · Routine
15 Apr · Routine
11 Apr · Routine
10 Apr · Routine
8 Apr · Routine
1 Apr · Routine
Mar 2024
28 Mar · Routine
28 Mar · Routine
28 Mar · Routine
22 Mar · Routine
21 Mar · Routine
18 Mar · Routine
13 Mar · Routine
13 Mar · Routine
11 Mar · Routine
7 Mar · Routine
5 Mar · Routine
Feb 2024
29 Feb · Routine
26 Feb · Routine
16 Feb · Routine
12 Feb · Routine
6 Feb · Routine
2 Feb · Routine
Jan 2024
31 Jan · Routine
29 Jan · Routine
23 Jan · Routine
19 Jan · Routine
16 Jan · Routine
12 Jan · Routine
9 Jan · Routine
5 Jan · Routine